Acquisition by Pfizer Global Blood Therapeutics was acquired by Pfizer for $5.4 billion, presenting potential collaboration or cross-selling opportunities within Pfizer's network and resources.

Treatment Development GBT Germany GmbH is actively developing treatments for beta thalassemia and sickle cell disease, indicating a growing market need and potential for partnership with healthcare providers.

Phase 3 Study Launch GBT Germany GmbH launched a Phase 3 study for SCD patients, offering a chance for pharmaceutical companies or research institutions to collaborate in clinical trials or drug development initiatives.

Financial Stability With a revenue range of $50-100 million and a funding of $300 million, Global Blood Therapeutics demonstrates financial strength that could appeal to investors or funding partners for further expansion or research projects.

ESG Report Focus GBT's inaugural ESG report highlights its commitment to sustainability, opening doors for partnerships with environmentally focused organizations or investors interested in socially responsible initiatives.